Drug Profile
TMX 049
Alternative Names: TMX 049DN; TMX-049Latest Information Update: 11 Apr 2022
Price :
$50
*
At a glance
- Originator Teijin Pharma
- Class Antigouts; Uricosurics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic nephropathies; Gout; Hyperuricaemia
Most Recent Events
- 07 Apr 2022 XORTX Pharma receives notification of intent to grant from the United States Patent Office for a patent covering xanthine oxidase inhibitors
- 06 Apr 2021 XORTX Pharma has patent protection for the use of uric acid lowering agents to treat chronic progressing kidney disease, hypertension, insulin resistance, and diabetic nephropathy, in USA and Europe Union
- 06 Apr 2021 XORTX Pharma receives notification of intent to grant a patent covering the use of uric acid lowering agents to treat and prevent diabetic nephropathies, in European Union